Skip to content

Study · Case report or series · n = 1 · 2026

3 results

Semaglutide exposure in early pregnancy and pregnancy outcomes: A case report and review of literature.

Jin YC, Wu YH, Ma XS, Shi W, Wu ML, Hu QQ

Journal of gynecology obstetrics and human reproduction5 Feb 2026

PMID41654227 (opens in a new tab)DOI10.1016/j.jogoh.2026.103133 (opens in a new tab)PepBankPUB-41654227
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a woman with a pre-pregnancy BMI of 27.73 who took semaglutide 0.5 mg weekly until about 7 weeks of gestation, all prenatal screenings were normal.

    In plain wordsIn one woman who took semaglutide until about 7 weeks of pregnancy, all prenatal screening tests were normal.

    Peptide
    Semaglutide
    Outcome
    No significant changePrenatal screening results after early-pregnancy exposure
    Study

    n = 1

    Outcome group
    Labour and delivery outcomes · Reproductive and sexual health
    Studied dose
    0.5 mg once weekly · from before conception to about 7 weeks of gestationAs given in this study (human).

    Source sentences

    Summary
    All prenatal screenings, including nuchal translucency and four-dimensional color Doppler ultrasound, were normal.
    2 context sentences
    Summary · context
    She received semaglutide 0.5 mg once weekly, initiated before conception and continued until approximately 7 weeks of gestation, and discontinued treatment immediately upon recognition of pregnancy.
    Summary · context
    We report the case of a 37-year-old woman with a pre-pregnancy Body Mass Index (BMI) of 27.73 kg/m².
  2. 02HumanCase report or seriesSafety outcome

    In a woman exposed to semaglutide until about 7 weeks of gestation, a healthy male infant was delivered at nearly 40 weeks.

    In plain wordsIn one woman who took semaglutide in early pregnancy, a healthy baby boy was born at nearly 40 weeks.

    Peptide
    Semaglutide
    Outcome
    No significant changeDelivery outcome after early-pregnancy exposure
    Study

    n = 1

    Outcome group
    Labour and delivery outcomes · Reproductive and sexual health
    Studied dose
    0.5 mg once weekly · from before conception to about 7 weeks of gestationAs given in this study (human).

    Source sentences

    Summary
    She delivered a healthy male infant at nearly 40 weeks of gestation.
    2 context sentences
    Summary · context
    She received semaglutide 0.5 mg once weekly, initiated before conception and continued until approximately 7 weeks of gestation, and discontinued treatment immediately upon recognition of pregnancy.
    Summary · context
    We report the case of a 37-year-old woman with a pre-pregnancy Body Mass Index (BMI) of 27.73 kg/m².
  3. 03HumanCase report or seriesSafety outcome

    In the infant of a woman exposed to semaglutide in early pregnancy, no adverse outcomes were seen at 1 and 3 months of age.

    In plain wordsIn this one case, the baby showed no problems at 1 and 3 months of age.

    Peptide
    Semaglutide
    Outcome
    No significant changeInfant outcomes at 1 and 3 months
    Study

    n = 1

    Outcome group
    Labour and delivery outcomes · Reproductive and sexual health
    Studied dose
    0.5 mg once weekly · from before conception to about 7 weeks of gestationAs given in this study (human).

    Source sentences

    Summary
    The infant showed no adverse outcomes during follow-up assessments at 1 and 3 months of age.
    2 context sentences
    Summary · context
    She received semaglutide 0.5 mg once weekly, initiated before conception and continued until approximately 7 weeks of gestation, and discontinued treatment immediately upon recognition of pregnancy.
    Summary · context
    We report the case of a 37-year-old woman with a pre-pregnancy Body Mass Index (BMI) of 27.73 kg/m².

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.